Cognition Therapeutics

Thank you, @LBDAssoc for a productive annual meeting last week. We We were particularly touched by the panel of #DLB patients and their #caregivers who described the challenges of being heard by family and HCPs alike on their journey to a diagnosis. #BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #DLBPsychosis #Lewybodydementia #DementiaResearch #BrainHealth #LewySTRONG

We're very much looking forward to this webinar. Thank you #LBDA for facilitating these educational events. It's important for those of us in the R&D space to continue to educate ourselves, and crucial for the greater community of patients, care partners and HCPs to build awareness of these complex diseases. #Parkinsonsdisease #DementiawithLewyBodies #LewyBodyDementia #Dementia #BrainHealth #DementiaSupport #LewySTRONG

April is #ParkinsonsAwarenessMonth. Did you know that about half of #Parkinsons patients will experience mild cognitive impairment (MCI) and about 20-30% of patients will develop #dementia, which can cause memory loss, confusion, mood changes, #hallucinations, or #delusions. Learn more at parkinson.org/understanding-…. #LewyBodyDementia #DementiaSupport #Psychosis #ParkinsonsDiseaseDementia

April is #ParkinsonsAwarenessMonth. Did you know that #ParkinsonsDisease impacts people in different ways? People may experience some or all of the symptoms of Parkinson's. Symptoms may present at different times in the disease course and may differ in severity from person to person. Learn more about Parkinson's disease at parkinson.org/awareness and help spread awareness. #DYK #ClinicalResearch #DementiaSupport

Thank you to the @VJDementia and Dr. James Galvin for taking time out of a busy #ADPD2026 to discuss the results from our Phase 2 study of #zervimesine in #dementia with Lewy bodies (DLB): tinyurl.com/2yucu3dq. #DementiaWithLewyBodies #DLBPsychosis #DementiaSupport #LewyStrong #Hallucinations #Delusions

$CGTX reported 4Q and YE2025 financial results last week: ir.cogrx.com/events/. During the webcast, CEO Lisa Ricciardi commented on the high level of interest in #zervimesine among participants in the DLB expanded access program. #BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #LewyBodyDementia #DementiaPsychosis #DLBPsychosis #DementiaSupport #LewyStrong

$CGTX reported 4Q and YE2025 financial results this morning and conducted a live webcast: ir.cogrx.com/events/. Management discussed plans to advance #zervimesine for the treatment of #psychosis associated with #dementia with Lewy bodies. #Pressrelease: tinyurl.com/23os8zbn #BiotechInnovation #ClinicalResearch #LewyBodyDementia #DementiaPsychosis #DLBPsychosis #DementiaSupport #LewyStrong #Hallucinations #Delusions

Thank you #ADPD2026 for another excellent meeting. The $CGTX team returned with a renewed excitement about the state of the science and clinical development in neurodegenerative diseases. #Neurology #ClinicalResearch #BiotechInnovation #neurodegeneration #DLBpsychosis #DementiaCare #DementiaSupport

$CGTX presented a post-hoc analysis from our Phase 2 #DLB study at #ADPD2026 showing that participants' psychological symptoms stabilized with #zervimesine treatment (102% slowing of decline relative to placebo on NPI-4). Poster: tinyurl.com/26e74vrq #BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #LewyBodyDementia #Dementia #DementiaCare #DementiaSupport #LewyStrong #Psychosis #Hallucinations #Delusions

The #CGTX team is presenting an analysis from the Phase 2 'SHIMMER' #DLB study at the #ADPD2026 Conference. #Pressrelease: tinyurl.com/26rh26be When assessed with the NPI-4, a diagnostic tool that measures changes in frequency and severity of #hallucinations, #delusions, #anxiety, and #agitation, participants on #zervimesine had a 102% slowing of decline relative to placebo. cogrx.com/pipeline/publi… #BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #LewyBodyDementia #Dementia #DementiaCare #DementiaSupport #LewyStrong #Psychosis #Neuroscience

$CGTX announced plans to advance development of #zervimesine (CT1812) for the treatment of #dementia with Lewy bodies (DLB) psychosis. Symptoms of #DLBPsychosis are reported to be extremely debilitating and often lead to institutionalization. #Pressrelease: tinyurl.com/23pm2dhy #BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #LewyBodyDementia #Dementia #DementiaCare #DementiaSupport #LewyStrong #Psychosis #Hallucinations #Delusions

Great article about the complexities of #dementia with Lewy bodies, the irrepressible nature of the human spirit, and the importance of an expert care team. #LewyBodyDementia #LewyStrong #ClinicalResearch #DementiaWithLewyBodies #DementiaCare #DementiaSupport

$CGTX announced that it has extended the duration of the expanded access program for #dementia with Lewy bodies. #Pressrelease: lnkd.in/eF_3aSRp Cognition’s CMO, Dr. Anthony Caggiano, added, “We’ve received favorable feedback during the program from participants and their care partners about their experience in this program.” #LewyBodyDementia #LewyStrong #ClinicalResearch #DementiaWithLewyBodies #Dementia #DementiaCare #DementiaSupport

January 28th is World Lewy Body Dementia Day. Learn more about the cause, diagnosis, and symptoms of LBD on the LBDA website: lbda.org #LewyBodyDementia #LewyStrong #ClinicalResearch #DementiaWithLewyBodies #Dementia #DementiaCare #DementiaSupport

$CGTX conducted a Type C meeting with the #FDA to review plans for a proposed Phase 2b study of zervimesine in #dementia with Lewy bodies (DLB). #Pressrelease: tinyurl.com/23vts78p #LewyBodyDementia #LewyStrong #ClinicalResearch #DementiaWithLewyBodies #DementiaCare #BiotechInnovation

It's the Friday before #JPMWeek. Slide decks are polished. Travel plans made. Looking forward to seeing old colleagues and making new connections next week at the #Sachs_NIF and Longwood Healthcare Leaders #SanFranciscoCEO meetings.

The journal, Alzheimer's & Dementia published “Phase 2 Study of Zervimesine (CT1812) in Participants with Mild-to-Moderate Dementia with Lewy Bodies (DLB)." The open-access article can be found here: alz-journals.onlinelibrary.wiley.com/doi/10.1002/al… #BiotechInnovation #ClinicalResearch #HealthcareInnovation #Dementia #DementiaCare #DementiaSupport #LewyStrong #DementiaWithLewyBodies

Great advice for #caregivers of people living with #dementia as we navigate this holiday season. #Alzheimers #AlzheimersDisease #DementiaCare #DementiaSupport #FamilyCaregivers

$CGTX announced that its #dementia with Lewy bodies (#DLB) expanded access program reached full enrollment: tinyurl.com/2b53eg3f. The program enrolled eligible SHIMMER participants who completed the Phase 2 study as well as additional DLB patients who met the enrollment criteria. #BiotechInnovation #ClinicalResearch #HealthcareInnovation #DementiaWithLewyBodies #LewyBodyDementia #DementiaCare #DementiaSupport #LewyStrong

$CGTX President and CEO, Lisa Ricciardi will participate in an “unplugged” fireside discussion at the annual Piper Sandler Healthcare Conference today at 4:30p.m. Eastern Time. Access the live audio here: event.webcasts.com/starthere.jsp?…. There will be an archive available on our events page following the conference: ir.cogrx.com/events. #BiotechInnovation #Biotechnology #Biotech #CNS #ClinicalResearch #HealthcareInnovation #DementiaWithLewyBodies #LewyBodyDementia #AlzheimersDisease #Alzheimers #HealthcareCEO #Leadership #Investing